Codexis Company Profile (NASDAQ:CDXS)

Analyst Ratings

Consensus Ratings for Codexis (NASDAQ:CDXS) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (45.99% upside)

Analysts' Ratings History for Codexis (NASDAQ:CDXS)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016HC WainwrightInitiated CoverageBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2015First AnalysisInitiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014Craig HallumInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Codexis (NASDAQ:CDXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q1($0.15)($0.11)$7.49 million$8.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q4($0.04)$0.02$11.63 million$11.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.11)$0.19$8.85 million$17.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.14)($0.14)$7.34 million$6.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.12)($0.14)$8.00 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414$0.01$0.07$13.30 million$14.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.06)($0.05)$9.00 million$7.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.15)($0.22)$8.50 million$6.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.10)($0.17)$10.00 million$7.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2014Q413($0.21)($0.26)$10.00 million$9.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.31)($0.24)$8.50 million$3.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q2 2013($0.28)($0.33)$9.00 million$6.97 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.36)($0.25)$7.63 million$11.48 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2013Q4 2012($0.34)($0.41)$9.33 million$7.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.15)($0.06)$25.88 million$26.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2012($0.15)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2012($0.11)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.08)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.10)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.07)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2011($0.06)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Codexis (NASDAQ:CDXS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.16)($0.08)($0.12)
Q2 20162$0.02$0.06$0.04
Q3 20162($0.13)($0.08)($0.11)
Q4 20162$0.05$0.07$0.06
Q1 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Codexis (NASDAQ:CDXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/11/2015James LalondeSVPSell9,441$3.52$33,232.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Patrick Y YangDirectorBuy10,000$3.47$34,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Bernard J. KelleyDirectorSell5,200$3.45$17,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Patrick Y YangDirectorBuy10,000$3.84$38,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Patrick Y YangDirectorBuy20,000$3.97$79,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Dennis P WolfDirectorSell35,416$4.10$145,205.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Patrick Y YangDirectorBuy20,000$2.35$47,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Patrick Y YangDirectorBuy20,000$2.34$46,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Patrick Y YangDirectorBuy60,000$2.22$133,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2013John J NicolsCEOBuy27,000$2.42$65,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2013John J NicolsCEOBuy54,000$2.22$119,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2013David D O'tooleCFOBuy10,000$2.02$20,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012David D O'tooleCFOBuy5,000$2.20$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012David D O'tooleCFOBuy5,000$2.78$13,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Douglas T SheehySVPSell3,800$2.76$10,488.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Codexis (NASDAQ:CDXS)
DateHeadline
07/01/16 05:02 PMETF’s with exposure to Codexis, Inc. : July 1, 2016 -
06/16/16 03:04 PMCODEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/02/16 06:15 AMCodexis to Present at Jefferies 2016 Healthcare Conference - [at noodls] - REDWOOD CITY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that President and CEO John Nicols and Senior Vice President and CFO ...
05/18/16 06:42 AMCodexis to Present at Upcoming Investment Conferences - [at noodls] - REDWOOD CITY, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: ...
05/17/16 01:15 PMCodexis, Inc. :CDXS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 03:37 PMEdited Transcript of CDXS earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 04:58 PMCodexis reports 1Q loss -
05/09/16 04:20 PMCODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition -
05/09/16 03:30 PMCodexis Inc Earnings Call scheduled for 4:30 pm ET today -
05/09/16 03:28 PMCodexis Reports Financial Results for the First Quarter of 2016 - [at noodls] - Revenues increase 18% to $8.0 million on significant growth in core biocatalyst R&D revenues and product sales Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif., May 09, 2016 ...
05/09/16 06:07 AMQ1 2016 Codexis Inc Earnings Release - After Market Close -
05/02/16 03:20 PMCodexis to Hold 2016 First Quarter Conference Call on May 9 - [at noodls] - REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2016 financial results after market ...
03/15/16 01:31 PMNew Broker Ratings For Codexis, Inc. (NASDAQ:CDXS) - FTSE News - New Broker Ratings For Codexis, Inc. (NASDAQ:CDXS)FTSE News12/17/2014 – Craig-Hallum began new coverage on Codexis, Inc. giving the company a “buy” rating. The share price of Codexis, Inc. (NASDAQ:CDXS) was up +2.21% during the last trading session, with a day high of 3.94. 3670 shares were traded on ...
03/15/16 01:31 PMCodexis, Inc. (NASDAQ:CDXS) Updated Price Targets - Share Trading News - Codexis, Inc. (NASDAQ:CDXS) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Codexis, Inc. (NASDAQ:CDXS). The most recent broker reports which have been released note that 0 analysts have a ...Q2 2016 Earnings Estimate for Codexis, Inc. Issued By First Analysis (CDXS)Intercooler FinancialCodexis Incorporated (NASDAQ:CDXS) Short Interest Decreased By 6.26%Business Standard Tribuneall 3 news articles »
03/09/16 10:36 AMCodexis, Inc. :CDXS-US: Earnings Analysis: 2015 By the Numbers -
03/08/16 04:15 PMCODEXIS INC Files SEC form 10-K, Annual Report -
03/04/16 07:20 PMEdited Transcript of CDXS earnings conference call or presentation 3-Mar-16 9:30pm GMT -
03/03/16 04:34 PMCodexis reports 4Q loss -
03/03/16 04:07 PMCODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/03/16 06:07 AMQ4 2015 Codexis Inc Earnings Release - After Market Close -
02/26/16 09:08 AMUpdated Price Targets On Codexis, Inc. (NASDAQ:CDXS) - Risers & Fallers - Updated Price Targets On Codexis, Inc. (NASDAQ:CDXS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Codexis, Inc. (NASDAQ:CDXS). The latest broker reports which are currently outstanding on Friday 26th of February state 0 analysts have a rating of “strong buy”, 3 ...
02/25/16 06:00 AMCodexis to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3 - [GlobeNewswire] - REDWOOD CITY, Calif., Feb. 25, 2016-- Codexis, Inc., a leading protein engineering company, announces that it will report fourth quarter and full year 2015 financial results after market close on Thursday, ...
02/23/16 04:22 PMCODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers -
02/22/16 07:21 AMCodexis Files Lawsuit against EnzymeWorks and CEO Junhua “Alex” Tao for Patent Infringement and Misappropriation of Trade Secrets - [Business Wire] - Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the filing of a lawsuit against EnzymeWorks and its founder, Junhua “Alex” Tao, for willful patent infringement, misappropriation of trade secrets, breach of confidence, and other claims.
02/20/16 01:42 PMCodexis Incorporated (NASDAQ:CDXS) Shorted Shares Increased By 6.85% - RiversideGazette.com - Codexis Incorporated (NASDAQ:CDXS) Shorted Shares Increased By 6.85%RiversideGazette.comThe short interest to Codexis Incorporated's float is 1.28%. The stock is down 0.24% or $0.01 after the news, hitting $4.09 per share. About 53,413 shares traded hands. Codexis, Inc. (NASDAQ:CDXS) has risen 5.64% since July 15, 2015 and is uptrending.
02/19/16 01:56 PMWhat's Ahead for Codexis, Inc. After Today's Huge Decline? - Sonoran Weekly Review - What's Ahead for Codexis, Inc. After Today's Huge Decline?Sonoran Weekly ReviewThe stock of Codexis, Inc. (NASDAQ:CDXS) is a huge mover today! The stock decreased 0.97% or $0.04 on February 17, hitting $4.1. About 90,107 shares traded hands. Codexis, Inc. (NASDAQ:CDXS) has risen 10.70% since July 13, 2015 and is uptrending.
02/13/16 12:58 PMCodexis Incorporated (NASDAQ:CDXS) Sellers Increased By 6.85% Their Shorts - fdanewsalert.com - Codexis Incorporated (NASDAQ:CDXS) Sellers Increased By 6.85% Their Shortsfdanewsalert.comThe short interest to Codexis Incorporated's float is 1.28%. The stock increased 4.10% or $0.16 on February 12, hitting $4.06. About 87,675 shares traded hands. Codexis, Inc. (NASDAQ:CDXS) has risen 11.54% since July 10, 2015 and is uptrending.
02/08/16 12:23 PMCodexis Incorporated (NASDAQ:CDXS) Shorted Shares Increased By 18.52% - fdanewsalert.com - Codexis Incorporated (NASDAQ:CDXS) Shorted Shares Increased By 18.52%fdanewsalert.comThe short interest to Codexis Incorporated's float is 1.2%. The stock is up 0.32% or $0.01 after the news, hitting $3.92 per share. About 26,737 shares traded hands. Codexis, Inc. (NASDAQ:CDXS) has risen 0.26% since July 2, 2015 and is uptrending.
02/04/16 11:52 AMCodexis, Inc. (NASDAQ:CDXS) Recent Analyst Updates - Risers & Fallers - Codexis, Inc. (NASDAQ:CDXS) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Codexis, Inc. (NASDAQ:CDXS). According to the latest broker reports outstanding on Wednesday 3rd February, 0 analysts have a rating of “strong buy”, 3 analysts “buy”, ...
02/01/16 11:22 AMCompany Shares of Codexis, Inc. (NASDAQ:CDXS) Drops by -1.22% - Bull Report - Company Shares of Codexis, Inc. (NASDAQ:CDXS) Drops by -1.22%Bull ReportCodexis, Inc. (NASDAQ:CDXS) has lost 1.22% during the past week and dropped 4.26% in the last 4 weeks. The shares has underperformed the S&P 500 by 2.92% during the past week but Codexis, Inc. (NASDAQ:CDXS) has outperformed the index in 4 ...
01/27/16 10:59 AMAnalyst Coverage Updates - Codexis, Inc. (NASDAQ:CDXS) - Risers & Fallers - Seeking AlphaAnalyst Coverage Updates - Codexis, Inc. (NASDAQ:CDXS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Codexis, Inc. (NASDAQ:CDXS). The latest broker reports which are currently outstanding on Wednesday 27th January state 0 analysts have a rating of “strong buy”, 3 analysts ...Codexis: A Three-Pronged Approach To Monetizing Its Game-Changing TechnologySeeking Alphaall 2 news articles »
01/27/16 10:59 AMCodexis: A Three-Pronged Approach To Monetizing Its Game-Changing Technology - Codexis Inc. (NASDAQ:CDXS) is a developer of biocatalysts used in the pharmaceutical, food and chemical industries in order to help to accelerate the research and manufacturing processes of its customers. Biocatalysts are naturally occurring chemical ...
01/25/16 10:51 AMCompany Shares of Codexis, Inc. (NASDAQ:CDXS) Rally 7.61% - WallStreet Prudent - Company Shares of Codexis, Inc. (NASDAQ:CDXS) Rally 7.61%WallStreet PrudentShares of Codexis, Inc. (NASDAQ:CDXS) rose by 7.61% in the past week and 2.76% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 6.11% and the outperformance increases to 11.06% for the last 4 weeks. Codexis, Inc. is ...
01/25/16 07:15 AMCodexis (CDXS) Catches Eye: Stock Adds 7.9% in Session -
01/19/16 04:07 PMCodexis (CDXS) Strong Industry, Solid Earnings Estimate Revisions -
01/06/16 11:51 AMWhy This Codexis Analyst Is Confident Stock Is Worth $6 -
01/06/16 06:06 AMCoverage initiated on Codexis by H.C. Wainwright -
12/24/15 09:39 AMCodexis, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/23/15 07:38 AMCan Codexis (CDXS) Stock Continue to Grow Earnings? -
12/22/15 03:18 PMCODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State -
12/18/15 06:21 AMCodexis Signs Multi-year Extension of Contract with Merck to Supply Enzyme Used in Manufacture of Sitagliptin - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemicals industry, announces the signing of an agreement extension with , known as MSD outside ...
12/15/15 07:38 AM3 Reasons Momentum Stock Investors Will Love Codexis (CDXS) -
12/11/15 07:40 AMCodexis (CDXS) Looks Good: Stock Adds 6.1% in Session -
12/08/15 12:17 PMCODEXIS INC Financials -

Social

About Codexis

Codexis logoCodexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CDXS
  • CUSIP: 19200510
Key Metrics:
  • Previous Close: $4.11
  • 50 Day Moving Average: $4.11
  • 200 Day Moving Average: $3.79
  • P/E Ratio: N/A
  • P/E Growth: -1.19
  • Market Cap: $167.64M
  • Beta: -0.02
  • Current Year EPS Consensus Estimate: $-0.23 EPS
  • Next Year EPS Consensus Estimate: $-0.29 EPS
Additional Links:
Codexis (NASDAQ:CDXS) Chart for Sunday, July, 24, 2016